VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens

• Ibel Carri
• Erika Schwab
• Juan Carlos Trivino
• Erika M. von Euw
• Morten Nielsen
• José Mordoh
• María Marcela Barrio